Transamination of Aspartate forms which compound?
Which defect in the urea cycle is an X-linked disease?
What is the primary enzymatic source of ammonia production in urine?
Which amino acids accumulate in maple syrup urine disease?
What type of protein is keratin classified as?
Sweaty feet odor in urine is seen in which condition?
What does salvage purine synthesis refer to?
Which of the following organs does not primarily utilize the salvage pathway of purine nucleotide synthesis?
What is the end product of purine metabolism in humans?
Rate limiting step in pyrimidine synthesis?
NEET-PG 2013 - Biochemistry NEET-PG Practice Questions and MCQs
Question 101: Transamination of Aspartate forms which compound?
- A. Pyruvate
- B. Acetyl-CoA
- C. Oxaloacetate (Correct Answer)
- D. Alanine
Explanation: ***Oxaloacetate*** - **Aspartate** is transaminated by **aspartate aminotransferase (AST)**, transferring its alpha-amino group to **alpha-ketoglutarate**. - This reaction converts aspartate into its corresponding alpha-keto acid, which is **oxaloacetate**. *Pyruvate* - **Pyruvate** is the alpha-keto acid corresponding to the amino acid **alanine**. - Transamination of **alanine** yields **pyruvate**, not aspartate. *Acetyl-CoA* - **Acetyl-CoA** is not a direct product of amino acid transamination; it is formed from **pyruvate** or fatty acid oxidation. - It functions as a key metabolic intermediate in energy production and biosynthesis. *Alanine* - **Alanine** is an amino acid, and therefore a reactant in transamination reactions to form pyruvate, rather than a product of aspartate transamination. - While it can be formed from pyruvate via transamination, it is not formed from aspartate.
Question 102: Which defect in the urea cycle is an X-linked disease?
- A. Ornithine transcarbamylase (Correct Answer)
- B. Arginase
- C. Argininosuccinate synthase
- D. Carbamoyl phosphate synthetase I
Explanation: ***Ornithine transcarbamylase*** - **Ornithine transcarbamylase (OTC) deficiency** is the only **X-linked recessive** disorder among the urea cycle defects. - Males are usually more severely affected, while females can be symptomatic carriers. *Carbamoyl phosphate synthetase I* - **Carbamoyl phosphate synthetase I (CPS1) deficiency** is an **autosomal recessive** disorder. - It is one of the more severe urea cycle defects, leading to profound hyperammonemia. *Arginase* - **Arginase deficiency** (hyperargininemia) is an **autosomal recessive** disorder. - It typically presents with a distinct neurological phenotype, including spasticity and developmental delay. *Argininosuccinate synthase* - **Argininosuccinate synthase deficiency**, also known as **Citrullinemia type I**, is an **autosomal recessive** disorder. - It leads to the accumulation of **citrulline** and **ammonia** in the blood.
Question 103: What is the primary enzymatic source of ammonia production in urine?
- A. Glutaminase (Correct Answer)
- B. Urease
- C. Glutamate dehydrogenase
- D. Arginase
Explanation: ***Glutaminase*** - This enzyme catalyzes the **hydrolysis of glutamine** located predominantly in the cells of the **renal tubules**, producing **ammonia** (NH3) and glutamate. - This process is crucial for **acid-base balance**, as the ammonia can bind with excess hydrogen ions to form ammonium (NH4+), which is then excreted in the urine. *Urease* - This enzyme breaks down **urea into ammonia and carbon dioxide**, primarily produced by **bacteria**, not human renal cells, and contributes to ammonia in urine in cases of **urinary tract infections**. - While it produces ammonia, it is not the primary enzymatic source within the healthy human kidney for **acid-base regulation**. *Glutamate dehydrogenase* - This enzyme converts **glutamate into alpha-ketoglutarate and ammonia**, but its contribution to urinary ammonia production is secondary to glutaminase in the kidney. - Its primary role is in **oxidative deamination** and the interconversion of glutamate and alpha-ketoglutarate, acting in both mitochondrial and cytosolic compartments. *Arginase* - This enzyme is involved in the **urea cycle**, converting **arginine into urea and ornithine** in the liver. - While it is important for the detoxification of ammonia by converting it into urea for excretion, it **does not produce ammonia** in the kidney for urinary excretion.
Question 104: Which amino acids accumulate in maple syrup urine disease?
- A. Valine
- B. Leucine
- C. Isoleucine
- D. All branched-chain amino acids (Correct Answer)
Explanation: ***All branched-chain amino acids*** - Maple syrup urine disease (MSUD) is characterized by a deficiency in the **branched-chain alpha-keto acid dehydrogenase complex**, which is responsible for the breakdown of branched-chain amino acids (BCAAs). - This deficiency leads to the accumulation of **leucine, isoleucine, and valine**, along with their corresponding alpha-keto acids, in the blood and urine. - The distinctive **maple syrup odor** in the urine is caused by the accumulation of branched-chain keto acids derived from all three BCAAs. *Leucine* - While leucine is one of the BCAAs that accumulates in MSUD, it is not the *only* amino acid involved. - The accumulation of **leucine** is particularly associated with the severe neurological symptoms seen in MSUD, as it is the most neurotoxic of the three BCAAs. *Valine* - Valine is another BCAA that accumulates due to the metabolic block in MSUD. - However, the disease involves the accumulation of all three BCAAs, not just valine in isolation. *Isoleucine* - Isoleucine is the third BCAA that accumulates in MSUD due to the defective enzyme. - Like leucine and valine, isoleucine and its corresponding keto acid accumulate in blood and urine when the branched-chain alpha-keto acid dehydrogenase complex is deficient.
Question 105: What type of protein is keratin classified as?
- A. Conjugated protein
- B. Globular protein
- C. Cylindrical protein
- D. Fibrous protein (Correct Answer)
Explanation: ***Fibrous protein*** - **Keratin** is a structural protein characterized by its **elongated, filament-like structure**, which is typical of fibrous proteins. - Fibrous proteins like keratin provide **mechanical strength** and play a significant role in the structure of tissues such as skin, hair, and nails. - Other examples of fibrous proteins include collagen, elastin, and myosin. *Globular protein* - **Globular proteins** have a **compact, spherical shape** and are often water-soluble, serving functions like enzymes, transporters, or receptors (e.g., hemoglobin or albumin). - Keratin's primary role is structural, not catalytic or transport, and its shape is not compact or spherical. *Cylindrical protein* - While some proteins might have a somewhat elongated or tube-like structure, **"cylindrical protein" is not a standard biochemical classification** of protein type. - This term does not accurately describe the characteristic fibrous nature and function of keratin. *Conjugated protein* - **Conjugated proteins** contain a non-protein component (prosthetic group) such as a carbohydrate, lipid, or metal ion attached to the protein (e.g., glycoproteins, lipoproteins, hemoglobin). - Keratin is a **simple fibrous protein** composed only of amino acids without prosthetic groups, so it is not classified as a conjugated protein.
Question 106: Sweaty feet odor in urine is seen in which condition?
- A. Phenylketonuria
- B. Isovaleric acidemia (Correct Answer)
- C. Alkaptonuria
- D. Maple syrup urine disease
Explanation: ***Isovaleric acidemia*** - This condition is characterized by a distinctive "sweaty feet" odor in body fluids, including urine, due to the accumulation of **isovaleric acid**. - It results from a deficiency in the enzyme **isovaleryl-CoA dehydrogenase**, which is crucial for leucine metabolism. *Phenylketonuria* - Patients with **phenylketonuria (PKU)** typically have a "mousy" or "musty" odor in their urine, not a sweaty feet smell. - This is due to the accumulation of **phenylalanine** and its metabolites. *Maple syrup urine disease* - This metabolic disorder is named for the characteristic sweet, maple syrup-like odor of the urine, which is distinctly different from a sweaty feet odor. - It is caused by a defect in the metabolism of **branched-chain amino acids (leucine, isoleucine, and valine)**. *Alkaptonuria* - This condition is known for urine that turns **dark brown or black** upon standing or when exposed to air, due to the oxidation of **homogentisic acid**. - It does not produce a sweaty feet odor.
Question 107: What does salvage purine synthesis refer to?
- A. Synthesis of purine nucleotides from purine bases (Correct Answer)
- B. Synthesis of purine nucleotides from ribose-5-phosphate
- C. Synthesis of purine nucleotides from simple precursors (de novo synthesis)
- D. Synthesis of purine nucleotides from degraded RNA
Explanation: ***Synthesis of purine nucleotides from purine bases*** - **Salvage pathways** recycle pre-existing purine or pyrimidine bases (from nucleic acid degradation) by re-attaching them to a **ribose phosphate** to form a new nucleotide. - This process is energy-efficient as it bypasses several steps of the de novo synthesis pathway, utilizing enzymes like **adenine phosphoribosyltransferase (APRT)** and **hypoxanthine-guanine phosphoribosyltransferase (HGPRT)**. *Synthesis of purine nucleotides from ribose-5-phosphate.* - While **ribose-5-phosphate** is a precursor, the complete synthesis from this molecule is part of the **de novo pathway**, which starts with PRPP (phosphoribosyl pyrophosphate) formation from ribose-5-phosphate. - This option does not specify the direct reuse of a pre-formed purine base, which is the hallmark of salvage. *Synthesis of purine nucleotides from simple precursors (de novo synthesis).* - **De novo synthesis** is the creation of nucleotides from scratch using simple metabolic precursors like amino acids (glycine, aspartate, glutamine), CO2, and THF derivatives. - This contrasts with salvage pathways, which recycle existing bases. *Synthesis of purine nucleotides from degraded RNA.* - Degraded RNA breaks down into **nucleotides**, which can then be further broken down into **purine bases** and ribose phosphates. - The direct synthesis of purine nucleotides from *degraded RNA* involves recovering the individual bases or nucleosides, then converting them to nucleotides via salvage, not directly using the entire degraded RNA.
Question 108: Which of the following organs does not primarily utilize the salvage pathway of purine nucleotide synthesis?
- A. RBC
- B. Leukocytes
- C. Liver (Correct Answer)
- D. Brain
Explanation: ***Liver*** - The **liver** is capable of both *de novo* synthesis and the salvage pathway of purine nucleotides, but it primarily utilizes the **de novo pathway** due to its high metabolic capacity and central role in biosynthesis for the entire body. - While salvage pathways exist, the liver's robust *de novo* synthesis allows it to readily produce purines from simple precursors, making it less reliant on salvaging pre-formed bases. *Brain* - The **brain** relies heavily on the **salvage pathway** for purine nucleotide synthesis because it has a limited capacity for *de novo* purine synthesis. - This dependency makes the brain particularly vulnerable to deficiencies in salvage enzymes, such as in **Lesch-Nyhan syndrome** where HGPRT deficiency leads to severe neurological dysfunction. *RBC* - **Red blood cells (RBCs)** are anucleated and lack the machinery for *de novo* purine synthesis, making them entirely dependent on the **salvage pathway** to maintain their purine nucleotide pool. - They salvage pre-formed purine bases and nucleosides from the plasma to synthesize necessary adenine and guanine nucleotides. *Leukocytes* - **Leukocytes**, particularly lymphocytes, have a high turn-over rate and metabolic activity, and they primarily rely on the **salvage pathway** for purine nucleotide synthesis. - The **immune system's rapid proliferation** and response demand efficient nucleotide synthesis, and the salvage pathway offers a quick and energy-efficient way to achieve this.
Question 109: What is the end product of purine metabolism in humans?
- A. Uric acid (Correct Answer)
- B. Carbon Dioxide
- C. Allantoin
- D. None of the options
Explanation: ***Uric acid*** - **Uric acid** is the final breakdown product of **purine metabolism** in humans. - It is formed from the degradation of **adenosine** and **guanosine**, with xanthine oxidase playing a key role in its synthesis. *Allantoin* - **Allantoin** is the end product of **purine metabolism** in most mammals other than primates, as they possess the enzyme **uricase** to further break down uric acid. - Humans lack **uricase**, hence allantoin is not the end product in humans. *Carbon Dioxide* - **Carbon dioxide** is a major end product of **carbohydrate** and **fat metabolism** through cellular respiration. - It is not directly associated with the degradation pathway of purines. *None of the options* - This option is incorrect because **uric acid** is indeed the definitive end product of purine metabolism in humans.
Question 110: Rate limiting step in pyrimidine synthesis?
- A. Aspartate transcarbamoylase (ATCase)
- B. Dihydroorotate dehydrogenase
- C. Dihydro-orotase
- D. Carbamoyl phosphate synthase-II (Correct Answer)
Explanation: ***Carbamoyl phosphate synthetase II (CPS-II)*** - **CPS-II** is the **committed and rate-limiting enzyme** in **de novo pyrimidine synthesis** in **mammals (including humans)** - It catalyzes the formation of **carbamoyl phosphate** from glutamine, CO₂, and 2 ATP in the **cytoplasm** - This is the **first committed step** and the main **regulatory checkpoint**, inhibited by UTP (feedback inhibition) and activated by PRPP and ATP - CPS-II is part of the **CAD complex** (carbamoyl phosphate synthetase, aspartate transcarbamoylase, dihydroorotase) in mammals *Aspartate transcarbamoylase (ATCase)* - ATCase catalyzes the **second step**: condensation of carbamoyl phosphate with aspartate to form carbamoyl aspartate - While ATCase is the **rate-limiting step in bacteria** (E. coli), in **mammals** it is part of the CAD complex and **not the primary regulatory step** - This option is incorrect for human/mammalian biochemistry tested in NEET PG *Dihydro-orotase* - The **third enzyme** in the pathway, converting carbamoyl aspartate to dihydroorotate - Part of the CAD complex in mammals but **not the rate-limiting step** *Dihydroorotate dehydrogenase* - Catalyzes the **fourth step**: oxidation of dihydroorotate to orotate - Located on the **outer surface of the inner mitochondrial membrane** (only mitochondrial enzyme in the pathway) - Important enzyme but **not rate-limiting**